The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lotz, C.
Right arrow Articles by Theobald, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotz, C.
Right arrow Articles by Theobald, M.
The Journal of Immunology, 2005, 175: 1301-1309.
Copyright © 2005 by The American Association of Immunologists

Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL1

Carina Lotz2,*, Sarah Abdel Mutallib*, Nicole Oehlrich*, Ulrike Liewer*, Edite Antunes Ferreira*, Marion Moos§, Michael Hundemer§, Sandra Schneider{ddagger}, Susanne Strand{dagger}, Christoph Huber*, Hartmut Goldschmidt§ and Matthias Theobald*

* Department of Hematology and Oncology and {dagger} Department of Gastroenterology, Johannes Gutenberg-University, and {ddagger} GANYMED Pharmaceuticals, Mainz, Germany; and § Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Growing evidence indicates that multiple myeloma (MM) and other malignancies are susceptible to CTL-based immune interventions. We studied whether transcription factors inherently involved in the terminal differentiation of mature B lymphocytes into malignant and nonmalignant plasma cells provide MM-associated CTL epitopes. HLA-A*0201 (A2.1) transgenic mice were used to identify A2.1-presented peptide Ag derived from the plasma cell-associated transcriptional regulators, positive regulatory domain I-binding factor 1 (PRDI-BF1) and X box-binding protein 1 (XBP-1). A2.1-restricted CTL specific for PRDI-BF1 and XBP-1 epitopes efficiently killed a variety of MM targets. PRDI-BF1- and XBP-1-reactive CTL were able to recognize primary MM cells from A2.1+ patients. Consistent with the expression pattern of both transcription factors beyond malignant and nonmalignant plasma cells, PRDI-BF1- and XBP-1-specific CTL activity was not entirely limited to MM targets, but was also associated with lysis of certain other malignancies and, in defined instances, with low-to-intermediate level recognition of a few types of normal cells. Our results also indicate that the A2.1-restricted, PRDI-BF1- and XBP-1-specific human CD8+ T cell repertoire is affected by partial self tolerance and may thus require the transfer of high-affinity TCR to break tolerance. We conclude that transcription factors governing terminal cellular differentiation may provide MM- and tumor-associated CTL epitopes.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The outcome of the majority of patients with multiple myeloma (MM)3 is unsatisfactory, although a proportion of patients benefit from high-dose therapy followed by autologous stem cell support (1). Allogeneic stem cell transplantation may result in higher complete response rates and, occasionally, in long-term survivors in true molecular remissions (1). This procedure, however, has yet been associated with substantial transplant-related mortality in MM patients (2). The advantages of allogeneic stem cell transplantation are the absence of MM cells in the graft and the existence of a CD8+ T cell-based graft-vs-myeloma effect (3, 4, 5). Clinical results, apart from donor lymphocyte infusions (3, 5, 6, 7), on a more specific CTL-mediated immunotherapy for MM are solely derived from vaccination trials using the Ig Id (8). The Id represents a private MM-associated Ag and thus cannot provide shared immunotherapy for various MM patients. Nonindividual MM-associated Ag, such as the cancer germline-specific MAGE/BAGE/GAGE/LAGE family gene products or mucin 1 (MUC1), have been identified (9). The expression pattern of MAGE-type genes, however, covers only a proportion (10–50%) of MM cells (9, 10). Although MUC1 has been reported to be expressed in 60–90% of MM samples (9, 11), only low-level cytotoxicity (20–30% specific lysis at E:T ratios of up to 100:1) in response to MM cells has been demonstrated for HLA-A*0201 (A2.1)-restricted CTL specific for the MUC1-derived peptide Ag M1.1 and M1.2 (11, 12). Hence, the identification of novel, MM-associated, MHC class I-presented CTL epitopes remains an important challenge. Moreover, Ag derived from proteins involved in the malignant phenotype are believed to be particularly useful for targeted anti-MM immune interventions, as the escape of neoplastic cells from immune recognition by the selection of Ag-loss variants would be less likely to occur (13, 14).

Naive B cells initiate a series of temporally and spatially regulated events that lead to the differentiation of both memory B cells and Ab-secreting plasma cells. Two transcription factors, the X box-binding protein 1 (XBP-1) and the mouse B lymphocyte-induced maturation protein 1 (Blimp-1) or its human homologue, the positive regulatory domain I-binding factor 1 (PRDI-BF1), have been recently demonstrated to be essential for terminal plasmacytic differentiation (15). XBP-1 was found to be required for the plasma cell phenotype, as no plasma cells develop in its absence (16). Blimp-1 has the unique ability to drive plasmacytic differentiation upon enforced expression in a B cell lymphoma cell line (17) or primary splenic B cells (18), and is found in all plasma cell types in vivo (19). More recently, an essential role for the transcription factor Blimp-1 in plasma cell differentiation and preplasma memory B cell formation has been defined (20). As with terminally differentiated nonmalignant plasma cells, MM cells have likewise been demonstrated to (over-)express mRNA and protein of XBP-1 and PRDI-BF1 (21, 22, 23, 24). Interestingly, however, PRDI-BF1 was found to be involved in additional terminal differentiation processes distinct from the B cell lineage (25), and XBP-1 expression did not appear to be exclusively specific for malignant and nonmalignant plasma cells (26).

In this study, we report on a novel concept for the immunotherapy of MM and other malignancies based on the induction of PRDI-BF1- and XBP-1-specific CTL. By circumventing self tolerance in A2.1 transgenic (Tg) mice (13, 14, 27), we identified several endogenously processed, A2.1-presented PRDI-BF1- and XBP-1-derived CTL epitopes. We show the entire response pattern of Tg mice-derived CTL, including the recognition of primary MM cells, malignant melanoma, breast, and hepatocellular cancer targets. Our results also indicate that the human T cell repertoire is affected by partial PRDI-BF-1- and XBP-1-specific self tolerance.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Tg mice (28) were kindly provided by L. A. Sherman (The Scripps Research Institute (TSRI), La Jolla, CA). Homozygous line cA2Kb, as compared with A2Kb mice, was derived from a different founder animal and had a 3-fold higher transgene expression. C57BL/6 mice were purchased from the breeding colony of the Johannes Gutenberg-University (JGU). Mice were maintained at the animal facility of JGU. Experimental procedures were performed according to German federal and state regulations and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

Peptides

PRDI-BF1 (377–386) (FLLPPYGMNC), (401–410) (FGLFPRLCPV), (402–410) (GLFPRLCPV), (406–414) (RLCPVYSNL), (406–415) (RLCPVYSNLL), and XBP-1 (18–27) (LLLSGQPASA), (19–27) (LLSGQPASA), influenza virus matrix protein (FluM1) (58–66) (GILGFVFTL), human tyrosinase (hTyr) (369–377) (YMDGTMSQV), hepatitis B virus core (128–140) (TPPAYRPPNAPIL) (29), human wild-type p53 (264–272) (LLGRNSFEV), vesicular stomatitis virus nucleoprotein (VSV-N) (52–59) (RGYVYQGL) (13), and HIV type 1 reverse transcriptase (HIV-RT) (476–484) (ILKEPVHGV) (30) peptides were synthesized by Affina Immuntechnik or Neosystem. Purity of synthetic peptides was ascertained by reversed phase high-performance liquid chromatography and mass spectrometry and was >80%. Purity of PRDI-BF1 (401–410) and (402–410) peptides was >97%.

Cells

MM cell lines were the A2.1+ U266 (American Type Culture Collection (ATCC) TIB 196), DEPU (LB-1696) (kindly provided by N. von Baren, Ludwig Institute for Cancer Research, Brussels, Belgium), L363, OPM-2 (14), and A2.1– NCI-H929 (ATCC CRL-9068). A2.1+ EBV-transformed B-lymphoblastoid cell lines (B-LCL) were SY (31), MC-CAR (ATCC CRL-8083), JY, and IM9 (14). Pre-B acute leukemia cell lines (pre-B-ALL) were the A2.1+ EU3 and UoC-B11 (14), and the A2.1– EU1 and UoC-B1 (14). A2.1+ tumor lines were the osteosarcoma U2OS (14), the colorectal cancer SW480, the breast cancers BT549 and MCF7 (13), the cervix carcinoma CaSki (ATCC CRL 1550), the hepatocellular carcinoma HepG2 (ATCC HB-8065), and the melanomas Malme 3M (ATCC HTB-64) and NA8-Mel (31), kindly provided by T. Wölfel (JGU). The TAP-deficient cell line T2 and the mouse thymoma EL4 have been described (13). K562 (ATCC CCL-243) were used as NK cell-sensitive target.

Monocyte-derived mature dendritic cells (DC) were generated under serum-free conditions as described (14, 31). The maturation state of DC was ascertained by flow cytometry including anti-CD83 staining. Isolated PBMC were polyclonally activated for 3 days in the presence of anti-CD3/CD28 Dynabeads (Dynal) and human rIL-2 (Proleukin; Chiron) at 40 U/ml. Purified T and B cells were obtained by negative selection of PBMC using Dynabeads (Dynal) labeled with anti-CD19 plus anti-CD14 or anti-CD2 plus anti-CD14 mAb, respectively. A2.1+ lung fibroblasts were purchased from ATCC (MRC-5, ATCC CCL-171). A2.1+ hepatocytes were prepared from healthy liver tissue obtained, after informed consent, during hepatic surgery. Human B cell lines were generated from adherent PBMC. Cells were resuspended in culture medium supplemented with autologous serum, human rIL-4 at 100 U/ml, and ciclosporin A for 3 wk at 5.5 x 10–7 M. Cells were seeded on irradiated (60 Gy) NIH3T3-CD154 transfectants and restimulated every 3–5 days. Growth and activation of CD154-CD40-induced B cells was tested weekly by flow cytometry. Primary MM cells were obtained from bone marrow (BM) samples of patients with MM after informed consent. Briefly, plasma cells were isolated from mononuclear cells with anti-human CD138 microbeads (Miltenyi Biotec) using the AutoMACS separation system (Miltenyi Biotec). Plasma cell purity of >90% was confirmed by flow cytometry.

Tg mouse and DC-stimulated human T lymphocytes were generated as reported (31). For the induction of human T cells stimulated with autologous CD154-CD40-activated B cells, PBMC following adherence were cultured at a 4:1 ratio in the presence of autologous serum, rIL-7 at 50 U/ml (days 1–21), rIL-7 at 50 U/ml plus rIL-2 at 100 U/ml (days 21–28), or rIL-2 at 100 U/ml (post-day 28) with 30 Gy-irradiated B cells that had been loaded with the indicated peptides at 10–5 M. The derivation of an A2.1-restricted CTL line specific for FluM1 (58–66) (CTL CD8 x A2Kb FluM1) has been described (31). An alloreactive A2.1-specific CTL line (CTL CD8 Allo A2) was established as reported (13). CTL were used as effector cells in 4–6 h standard 51Cr-release and ELISPOT assays. Cold target inhibition was performed by adding cold T2 cells loaded with either the relevant or an irrelevant control peptide at 10–5 M to hot targets at a cold:hot target ratio of 20:1 before incubation with the CTL. As indicated, target cells were preincubated with the anti-A2 mAbs MA2.1 or PA2.1 (13).

Peptide binding to A2.1

A competition assay (13) was used to assess binding of synthetic PRDI-BF1 and XBP-1 peptides to A2.1. T2 cells were pulsed with 0.01 µg of the A2.1-binding peptide p53 (264–272) and either 3 or 10 µg of PRDI-BF1/XBP-1 peptides. The A2.1-restricted p53 (264–272)-specific CTL line, CD8 x A2 264, was assayed at various E:T ratios for lytic activity in response to peptide- and nonpeptide-pulsed T2 targets in a 4 h 51Cr-release assay. Percent inhibition of CD8 x A2 264 CTL-mediated lysis of p53 (264–272)-pulsed T2 cells by the PRDI-BF1/XBP-1 peptides was calculated at an E:T ratio of 1:1. The H-2Kb-binding VSV-N (52–59) and the A2.1-binding FluM1 (58–66) peptides served as negative and positive control, respectively.

Inhibiting proteasomal Ag production

OPM-2 cells were washed in HBSS and exposed for 1 min to 0.13 M citric acid/0.061 M Na2HPO4 (pH 3.0) (14, 32). Cells were washed in RPMI 1640 and cultured for 5 h with or without lactacystin (Boston Biochem) at 10 and 30 µM. Cells were used as targets in a 5.5 h 51Cr-release assay in the continuous presence or absence of lactacystin (14, 32).

ELISPOT assay

IFN-{gamma} secretion by human and murine effector T cells was determined by ELISPOT assays that take advantage of anti-IFN-{gamma} capture mAb (human IFN-{gamma}: 1D1K; Mabtech/mouse IFN-{gamma}: RMMG-1; Biosource Europe) and detection mAb (human IFN-{gamma}: 7-B6-1; Mabtech/mouse IFN-{gamma}: XMG 1.2; BD Biosciences) (33). The number of IFN-{gamma} spots was determined by an automated and computer-assisted video-image analyzer (Zeiss-Kontron). Briefly, DC-activated human effector T cells were cocultured under serum-free conditions at 0.3 or 1 x 105 cells/well with 0.5 x 105 target cells. Ag specificity of human T cells was evaluated by adding test or control peptides at a final concentration of 10–5 M. PHA (2 µg/ml) supplemented cocultures served as additional positive controls. Human B cell-stimulated T cells at 6 x 104, 2 x 104, and 1 x 104 were tested in response to 3 x 104 T2 cells loaded with PRDI-BF1 and XBP-1 peptides at various concentrations. BM-derived CD138+ MM cells from A2.1+ MM patients served as target cells in mouse-IFN-{gamma} ELISPOT assays and were coincubated at 1 x 105 cells/well with 3 and 1.5 x 104 Tg mouse CTL. Normal CD 138– cells of the same patient-derived BM sample were adjusted at corresponding target numbers and used as control.

Real-time PCR analysis

Real-time analysis was performed using the ABI 7900HT (Applied Biosystems) with Absolute QPCR SYBR Green Rox Mix (ABgene) according to the manufacturer. Total RNA was isolated with an RNeasy Mini kit (Qiagen) from the indicated normal tissues and various tumor samples. Random-primed cDNA synthesis was performed using Superscript II (Invitrogen Life Technologies). For PRDI-BF1 and XBP-1 amplifications, the following primers were designed: PRDI-BF1 sense: 5'-GTACGACCTTGGCTGCCC-3'; PRDI-BF1 reverse: 5'-CGCCATCAGCACCAGAA-3'; XBP-1 sense: 5'-TTAGAAGAAGAGAACCAAAAAC-3'; XBP-1 reverse: 5'-ACGTAGTCTGAGTGCTG-3'. The amount of cDNA was determined by measuring the 18S levels of each sample (34). Relative expression values have been calculated using the {Delta}{Delta} threshold cycle (Ct) method.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Generating PRDI-BF1- and XBP-1-specific CTL in Tg mice

Based on consensus motifs and computational score models for A2.1-binding peptides (35, 36), we selected a total of 61 and 16 synthetic peptides corresponding to PRDI-BF1 and human XBP-1 protein sequences, respectively. Almost all of the PRDI-BF1 (32 of 44) and XBP-1 (11 of 13) peptides with strong-to-intermediate A2.1-binding capacity were tested for their ability to induce A2.1-restricted and peptide-specific CTL in A2.1 Tg mice to bypass potential self tolerance (data not shown). Immunogenic peptides representing PRDI-BF1 (377–386,401–410,402–410,406–414,406–415) as well as XBP-1 (18–27) and (19–27) aa were nonhomologous to mouse self-PRDI-BF1/-XBP-1 sequences. These peptides had strong A2.1-binding efficiencies, except of PRDI-BF1 (406–414) that bound to A2.1 with intermediate activity (Fig. 1). Using human CD8 x A2.1 or CD8 x (c)A2Kb double Tg mice, we generated A2.1-restricted CTL lines specific for these immunogenic peptides. PRDI-BF1 (406–414)- and (406–415)-reactive CTL required as much as 0.1 µM Ag to induce lysis of peptide-pulsed T2 cells (data not shown). Provided that these Ag would have been processed endogenously, such CTL were likely of too low an avidity to allow recognition of natural Ag. In contrast, CTL lines specific for PRDI-BF1 (377–386,401–410), and (402–410) required <10 nM of either stimulatory Ag to induce killing of peptide-pulsed T2 targets (Fig. 2, A–C). A common property of immunogenic PRDI-BF1 peptides was the presence of a cysteine within the sequence. Due to its free S-H group, cysteine is the most chemically reactive amino acid under physiological conditions. Peptide titration in the presence of a reducing agent and the use of synthetic peptide variants, in which the cysteine side chain was converted into a nonreactive form, suggested that cysteine modification based on oxidization of the free S-H group (37) has an impact on PRDI-BF1-specific CTL recognition. Although we found a 10-fold increase in peptide sensitivity of PRDI-BF1 (401–410)- and (402–410)-specific CTL under reducing conditions, no effect was observed for PRDI-BF1 (377–386)-reactive CTL or control CTL recognizing a non-cysteine-containing Ag (data not shown). By loading PRDI-BF1 peptide substitutes in which cysteine was replaced by alanine onto T2 targets, we found that PRDI-BF1 (377–386)- and (402–410)-stimulated CTL were up to 1 log more sensitive in recognizing the alanine substitutes (Fig. 2, A and C) at various E:T ratios and peptide doses (data not shown). This observation was not due to differences in A2.1 binding between alanine- and nonsubstituted peptides (data not shown). In contrast to PRDI-BF1 (377–386)- and (402–410)-specific CTL, effector T cells propagated with PRDI-BF1 (401–410), demonstrating a more profound lytic activity in response to the 9-mer PRDI-BF1 (402–410) than to the 10-mer (401–410) (Fig. 2B), did not substantially cross-recognize the alanine variants of PRDI-BF1 (401–410) or (402–410) (data not shown). Therefore, our results suggest the possibility of a differential sensitivity of PRDI-BF1 (377–386)-, (401–410)-, and (402–410)-specific CTL to cysteine-modified Ag.



View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 1. A2.1-binding activity of immunogenic PRDI-BF1 and XBP-1 peptides. A, The A2.1-binding activity, shown as percent inhibition, was determined by the ability of the indicated synthetic peptides to inhibit the A2.1-binding of the p53 (264–272) peptide. This was measured as inhibition of lysis by p53 (264–272)-specific CTL of T2 cells loaded with the corresponding p53 peptide and different concentrations of indicated PRDI-BF1 and XBP-1 peptides (as shown in B). Four experiments are summarized. Representative results are shown for the control competitor peptides, FluM1 (58–66) and VSV-N (52–59). The levels of control lyses in the presence of the antigenic p53 peptide but absence of competitor peptide (T2 + p53) and in the absence of any peptides (T2) are indicated.

 


View larger version (28K):
[in this window]
[in a new window]
  		FIGURE 2. Specificity, A2.1 restriction, and efficiency of Ag recognition by PRDI-BF1 and XBP-1 peptide-reactive CTL. CTL lines established from primary cultures of A, PRDI-BF1 (377–386)-, B, (401–410)-, C, (402–410)-, D, XBP-1 (18–27)-, and E, (19–27)-induced T cells were tested at various E:T ratios (shown: 10:1) for recognition of T2 targets pulsed with the stimulating peptide (•), the indicated peptide variant ({blacksquare}), or FluM1 (58–66) ({blacktriangleup}), and EL4 cells coated with the stimulating Ag ({circ}) or an unrelated A2.1-binding peptide ({triangleup}) at the indicated concentrations in a 5.5 h 51Cr-release assay.

 
Effector T cells obtained after restimulation with XBP-1 (18–27) and (19–27) required ~0.1 nM Ag for lysis of peptide-coated T2 targets (Fig. 2, D and E). We ascertained the Ag specificity and A2.1 restriction of all CTL lines based on their failure to lyse T2 cells loaded with the A2.1-binding FluM1 (58–66) peptide, and their lack of recognition of A2.1-negative EL4 targets coated with either stimulatory peptide (Fig. 2).

Targeting MM cells by PRDI-BF1- and XBP-1-specific CTL

MM cells have been demonstrated to (over-)express PRDI-BF1 and XBP-1 mRNA and protein (data not shown) (21, 22, 23, 24, 38). To assess whether the antigenic PRDI-BF1 and XBP-1 peptides represent naturally processed, A2.1-presented CTL epitopes, we explored MM targets for recognition by PRDI-BF1- and XBP-1-specific CTL. We found that A2.1+ as opposed to A2.1– (NCI-H929) MM cell lines were selectively killed by PRDI-BF1- and XBP-1-reactive CTL (Fig. 3, A–E). Effector T cells with specificity for PRDI-BF1 (402–410) were able to efficiently recognize the A2.1+ MM targets U266, OPM-2, L363, and DEPU (Fig. 3C). Comparable results were obtained for PRDI-BF1 (377–386)-specific CTL (Fig. 3A). Although PRDI-BF1 (401–410)- and (402–410)-reactive CTL were of almost equivalent avidity in response to the 9-mer (402–410) (Fig. 2, B and C), they differed substantially in their functional recognition of A2.1+ MM targets (Fig. 3, B and C). This finding would be consistent with the possibility of a differential sensitivity of these CTL to cysteine modified Ag (Fig. 2C and data not shown) (39).



View larger version (26K):
[in this window]
[in a new window]
  		FIGURE 3. Targeting MM cells by PRDI-BF1- and XBP-1-specific CTL. A, PRDI-BF1 (377–386)-, B, (401–410)-, C, (402–410)-, D, XBP-1 (18–27)-, and E, XBP-1 (19–27)-specific CTL lines as well as F, CD8 x A2Kb FluM1 and G, CD8 Allo A2 control CTL were tested for cytolytic activity to A2.1+ U266 (•), OPM-2 ({blacktriangleup}), OPM-2 treated with anti-A2 mAb ({triangleup}), L363 ({blacktriangledown}), L363 treated with anti-A2 mAb ({triangledown}),DEPU ({blacksquare}), DEPU treated with anti-A2 mAb ({square}), and A2.1– NCI-H929 ({diamond}) at the indicated E:T ratios in a 5.5 h 51Cr-release assay.

 
XBP-1 (19–27)- as compared with (18–27)-specific CTL gave rise to more robust A2.1-restricted lytic responses to the majority of A2.1+ MM targets (Fig. 3, D and E). Although mutual cross-recognition of the 9- and 10-mer peptide by XBP-1 (18–27)-reactive CTL, respectively, occurred only with anti-XBP-1 (18–27) effector T cells, this ability vanished upon their prolonged in vitro maintenance and was accompanied by impaired recognition of natural Ag presented on MM targets (data not shown). However, their avidity in response to the stimulatory Ag XBP-1 (18–27) itself was not affected. These findings indicate that XBP-1 (19–27) as opposed to (18–27) is the naturally processed CTL epitope.

Lack of killing of A2.1– NCI-H929 targets by PRDI-BF1- and XBP-1-reactive CTL (Fig. 3, A–E) as well as inhibition of the cytolytic response to A2.1+ MM cells in the presence of an anti-A2 mAb (Fig. 3, A, C, and E) revealed that MM recognition by PRDI-BF1- and XBP-1-specific CTL was in fact A2.1-restricted. Positive and negative responder controls for MM cell recognition were allo-A2.1-reactive and FluM1 (58–66)-specific T cell lines, respectively (Fig. 3, F and G). We conclude that defined PRDI-BF1- and XBP-1-derived peptides provide naturally processed, MM-associated CTL epitopes.

Peptides presented by class I MHC molecules are most often derived from proteolytic processing of cellular proteins by the 20S proteasomal complex (40). To study whether the epitopes recognized by PRDI-BF1- and XBP-1-specific CTL had been generated by the proteasome, proteasomal Ag production by OPM-2 cells was modified by lactacystin (32). Naturally presented peptides were stripped off cell surface class I MHC molecules of OPM-2 cells by acid treatment to allow only novel peptides generated by proteolytic degradation to be presented for CTL recognition (14, 32). Production of the MM-associated model CTL epitopes PRDI-BF1 (402–410) and XBP-1 (19–27) was inhibited by exposing OPM2 to lactacystin (Fig. 4, A and B), as was lysis by peptide-dependent allo-A2.1-reactive control CTL (Fig. 4D). No effect was observed with CTL CD8 x A2Kb FluM1 (58–66) used as a negative control (Fig. 4C), indicating that the treatment of OPM-2 targets with the proteasome inhibitor per se did not render them susceptible to CTL-mediated cell death. These findings demonstrate that the natural PRDI-BF1 and XBP-1 peptides recognized by CTL were endogenously processed by the proteasome complex.



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 4. Inhibition of proteasomal PRDI-BF1 and XBP-1 processing by lactacystin. Class I MHC-bound peptides were stripped off OPM-2 cells by acid treatment. OPM-2 were nonexposed (•) or exposed to lactacystin at 10 µM ({triangleup}) and 30 µM ({circ}), and tested in the continuous presence or absence of lactacystin for recognition by CTL. A, CD8 x A2Kb PRDI-BF1 402; B, CD8 x cA2Kb XBP-1 19; C, CD8 x A2Kb FluM1; and D, peptide-dependent CD8 Allo A2 at the indicated E:T ratios in a 5.5 h 51Cr-release assay.

 
To extend the analysis of PRDI-BF1- and XBP-1-specific CTL to primary MM cells, BM samples from A2.1+ MM patients were separated into the CD138+ MM subset and normal CD138– BM mononuclear cells. PRDI-BF1- and XBP-1-specific CTL produced IFN-{gamma} in response to freshly isolated MM as opposed to normal BM stimulators (Fig. 5A). Allo-A2.1- and FluM1 (58–66)-reactive CTL were used as positive and negative responder control, respectively. MM-specific cytolytic activity was only observed with PRDI-BF1 (402–410)- and (401–410)-specific T cells, albeit less efficiently (Fig. 5B). Comparable results were obtained with BM samples from four of six MM patients. Obviously, primary MM cells freshly isolated from A2.1+ patients are targeted by PRDI-BF1- and XBP-1-reactive effector T cells. Lack of recognition of CD138– BM targets also precludes the possibility that PRDI-BF1- and XBP-1-reactive T lymphocytes cross-recognized other non-MM cell-derived peptides or responded by peptide-dependent allorecognition.



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 5. Recognition of primary MM targets by XBP-1- and PRDI-BF1-reactive T cells. BM samples from A2.1+ MM patients were separated into the CD138+ MM subset and normal CD138– BM mononuclear cells and used as targets in A, IFN-{gamma} ELISPOT, and B, 51 Cr-release assays. A, IFN-{gamma} secretion of the indicated XBP-1- and PRDI-BF1-specific effector T cells is shown in response to the CD138+ vs the CD138– BM fraction of one MM patient. CTL were used at 1.5 x 104 per well resulting in the indicated E:T ratios. Allo-A2.1- and FluM1 (58–66)-reactive CTL were used as positive and negative responder control, respectively. The absolute numbers of spots are indicated. Comparable results were obtained with BM samples from four of six MM patients. B, Cytolytic activity of CTL CD8 x A2Kb PRDI-BF1 402 and CD8 x A2Kb PRDI-BF1 401 to CD138+ (•) vs CD138– ({circ}) BM cells of the same MM patient was measured at the indicated E:T ratios in a 5.5 h 51Cr-release assay.

 
PRDI-BF1- and XBP-1-specific CTL activity beyond MM targets

PRDI-BF1-/XBP-1-targeted immunotherapy would ideally be associated with selective killing of malignant targets and, perhaps, nonmalignant plasma cells while preserving other nontransformed tissues. Recent observations, however, have indicated a broader expression pattern of PRDI-BF1 than has so far been anticipated, arguing for its involvement in additional terminal differentiation processes distinct from the B cell lineage (25). XBP-1, too, has been found expressed in other tissues, including the liver (16, 41). These findings led us to study PRDI-BF1- and XBP-1-specific CTL in response to other non-MM-related B cell malignancies and B-LCL, various solid tumor cells, and nontransformed targets (Fig. 6). FluM1 (58–66)- and allo-A2.1-reactive effector T cells were used as controls (data not shown).



View larger version (35K):
[in this window]
[in a new window]
  		FIGURE 6. PRDI-BF1- and XBP-1-specific CTL activity beyond MM targets. CTL specific for A, PRDI-BF1 (377–386), B, (401–410), C, (402–410), and D, XBP-1 (19–27) were tested at E:T ratios of 30:1 for recognition of the indicated targets in 5.5 h 51Cr-release assays. All target cells, except of EU1 and UoC-B1 controls, were A2.1+. As indicated, targets were preincubated with an anti-A2 mAb (+ Ab) or were mixed at a ratio of 1:20 with cold T2 cells either loaded (at 10–5 M) with the relevant PRDI-BF1 or XBP-1 peptides (+ c.t.) or an irrelevant control peptide (control) before incubation with the CTL. A–D, CTL recognition of targets after cold target inhibition or anti-A2 mAb treatment is shown at E:T ratios of 10:1. Representative results are shown for CTL recognition of normal targets obtained from two different donors.

 
PRDI-BF1-reactive CTL responded to the majority of EBV-transformed B-LCL, the PRDI-BF1+ osteosarcoma line U2OS (42), and the melanoma targets NA8-Mel and Malme 3M, whereas pre B-ALL were mostly ignored (Fig. 6, A–C). These results are in accordance with expression analyses of the mouse homologue of PRDI-BF1, Blimp-1 (17). The differential capacity of PRDI-BF1-specific CTL to respond to transformed A2.1+/PRDI-BF1+ cells, as shown in Figs. 3, A–C, and 6, A–C, was also observed with nontransformed targets. Whereas all normal cells were ignored by PRDI-BF1 (377–386)-reactive effector T cells (Fig. 6A), low level recognition of mature DC (25% lysis) by CTL PRDI-BF1 (401–410) in one of three experiments and of PBMC (20% lysis) by CTL PRDI-BF1 (402–410) occurred (Fig. 6, B and C). PRDI-BF1 (402–410)-specific CTL gave also rise to ~45% specific lysis of purified B cells (Fig. 6C). Interestingly, formation of (preplasma) memory B cells has been demonstrated more recently to require the expression of Blimp-1 (20). Taken together, the overall pattern of cytolytic responses revealed for the different PRDI-BF1-specific CTL (Figs. 3, A–C, and 6, A–C) seemed to be cogoverned by their individual avidity (Fig. 2, A–C).

Effector T cells with specificity for XBP-1 (18–27) and (19–27) did not distinguish between different B cell malignancies and efficiently killed all A2.1+ EBV-transformed B-LCL and pre B-ALL lines while ignoring the A2.1– pre B-ALL targets, EU1 and UoC-B1 (Fig. 6D and data not shown). XBP-1-reactive CTL also recognized NA8-Mel and Malme 3M melanoma cells, whereas additional cytolytic activity in response to breast cancer (BT549) and hepatocellular carcinoma (HepG2) targets was only revealed for XBP-1 (19–27)-specific CTL (Fig. 6D and data not shown). Lysis of HepG2 cells by XBP-1 (19–27)-stimulated CTL is consistent with XBP-1 expression in hepatocellular carcinomas (43). Its level of expression in adult human liver (43), however, was not sufficient to allow XBP-1-specific killing of normal A2.1+ hepatocytes isolated from two different sources (Fig. 6D and data not shown). The differential avidity of XBP-1-reactive CTL in recognizing the (19–27) epitope became more apparent in their responses to other nontransformed cells. Although normal targets were ignored by XBP-1 (18–27)-reactive CTL, XBP-1 (19–27)-specific effector T cells demonstrated intermediate level killing of A2.1+ mature DC (40% lysis) (Fig. 6D and data not shown). Mature DC are believed to be protected from CTL-mediated apoptosis by expression of the granzyme inhibitor, serine protease inhibitor-6 (44). The observed anti-DC T cell responses could be due to the readout via the 51Cr-release as opposed to other assays, such as JAM, that are based on DNA fragmentation (44, 45).

Inhibition of the cytolytic response to the A2.1+ melanoma cell line Malme 3M and purified B cells in the presence of an anti-A2 mAb (Fig. 6, C and D) revealed that recognition of non-MM tumor targets and nontransformed B cells by PRDI-BF1- and XBP-1-specific CTL was indeed A2.1-restricted. Cold target inhibition of MM cell killing by PRDI-BF1- and XBP-1-reactive CTL (Fig. 6) as well as B cell and mature DC recognition by XBP-1-reactive CTL (Fig. 6D) again demonstrated the Ag specificity of these effector T cells and precludes the possibility that PRDI-BF1- and XBP-1-reactive CTL cross-recognized other non-PRDI-BF1- or non-XBP-1-derived peptides.

Based on these results and the expression patterns of PRDI-BF1 and XBP-1 (16, 17, 20, 25, 26, 38, 41), we conclude that PRDI-BF1- and XBP-1-reactive CTL activity is not entirely limited to MM targets, but is also associated with lysis of other malignancies and, in the case of PRDI-BF1 (401–410)-, (402–410)-, and XBP-1 (19–27)-, but not PRDI-BF1 (377–386)-specific CTL, with low-to-intermediate level recognition of a few types of nontransformed cells.

Consistent with these observations, we found expression of PRDI-BF1 and XBP-1 transcripts in a number of normal tissues (Fig. 7). However, expression levels were 4-fold lower as compared with a MM standard (NCI-H929) (Fig. 7). XBP-1 CTL-mediated lysis of BT549 and HepG2 as opposed to normal hepatocytes (Fig. 6D) seemed to correlate with elevated XBP-1 transcripts in breast and hepatocellular cancer relative to normal breast and liver (Fig. 7). The PRDI-BF1 and XBP-1 RNA expression in normal bone marrow (Fig. 7), however, was not associated with susceptibility to Ag-specific CTL recognition (Fig. 5).



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 7. PRDI-BF1 and XBP-1 RNA expression in various normal tissues. Expression levels of PRDI-BF1 and XBP-1 transcripts in the indicated normal and tumor samples were studied by real-time PCR. In brief, the Ct for PRDI-BF1, XBP-1, and control 18S RNA were determined for each sample and normalized to the Ct in muscle (PRDI-BF1 Ct = 32.69, XBP-1 Ct = 23.55, and 18S RNA Ct = 17.35).

 
Partial self tolerance to PRDI-BF1 and XBP-1 in the human CD8+ T cell repertoire

Supported by these findings, we wanted to confirm our prejudice that the human CD8+ T cell repertoire is affected by PRDI-BF1- and XBP-1-specific self tolerance. To this end, naive CD8+ T lymphocytes from at least two different A2.1+ healthy donors underwent in vitro stimulation with mature autologous DC that had been pulsed with either of the three relevant PRDI-BF1 Ag, XBP-1 (19–27), or the hTyr (369–377) control peptide. By using PRDI-BF1 (377–386) and (402–410) for CTL induction, the generated CD8+ T cell cultures were neither cytolytic nor did they secrete IFN-{gamma} in response to peptide-coated T2 targets (data not shown). In contrast, CD8+ T cells able to specifically secrete IFN-{gamma} upon challenge with peptide-loaded T2 targets were induced in all donors stimulated with PRDI-BF1 (401–410) and XBP-1 (19–27) (Fig. 8A). Interestingly, the PRDI-BF1 (401–410)-responding T cells cross-recognized T2 cells loaded with the 9-mer, PRDI-BF1 (402–410) (Fig. 8A). Ag specificity of effector T cells was demonstrated by their failure to secrete IFN-{gamma} upon challenge with HIV-RT peptide-coated targets (Fig. 8A). Specific killing of Ag-pulsed T2 cells was only observed for PRDI-BF1 (401–410)- and XBP-1 (19–27)-reactive CTL obtained from donor 1 (100 and 30% specific lysis at an E:T of 20:1, respectively), and required higher peptide concentrations (10–5 M) as compared with Tg mouse CTL (Fig. 2, B and E). The failure to promote CTL in nonresponding cultures was due to the use of PRDI-BF1 and XBP-1 peptides as hTyr (369–377)-specific and malignant melanoma-reactive cytolytic effector T cells were generated in all donors (Fig. 8A and data not shown) (31). As the number of PRDI-BF1 (401–410)- and XBP-1-reactive, DC-induced human CD8+ effector T cells was limited and their avidity appeared to be low to intermediate, we tested their capability of recognizing MM targets in the IFN-{gamma} ELISPOT assay. Likewise, only donor 1-derived CTL were capable of specifically secreting IFN-{gamma} in response to the A2.1+ MM cell lines L363 and U266 (Fig. 8B). MM cell recognition was A2.1-restricted and not affected by NK cell activity as no response to A2.1– NCI-H929 and K562 targets occurred (Fig. 8B). Corresponding effector T cells stimulated with hTyr (369–377) served as negative control (Fig. 8B).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 8. Specificity, A2.1-restriction, and anti-MM activity by human CD8+ T cells induced with PRDI-BF1 (401–410) and XBP-1 (19–27). Human CD8+ T lymphocytes isolated from at least two A2.1+ healthy donors and stimulated in parallel for five cycles with (left panel) PRDI-BF1 (401–410)-, (middle panel) XBP-1 (19–27)-, and (right panel) control hTyr (369–377)-pulsed autologous mature DC were tested for IFN-{gamma} secretion at the indicated E:T ratios in response to A, T2 cells coated with the indicated peptides at 10–5 M. B, PRDI-BF1 (401–410)- and XBP-1 (19–27)-induced CD8+ T cells from donor 1 and the due control stimulated with hTyr (369–377) were assayed for recognition of the A2.1+ MM cells L363 and U266, the A2.1– MM target NCI-H929, and the NK-sensitive K562 line.

 
To confirm these findings, human T cells from 10 different A2.1+ healthy donors were stimulated with CD154-CD40-activated autologous B cells that had been loaded with either of the PRDI-BF1 377 and 401 peptides or the XBP-1 19 Ag. Five of 10 donor T cells responded by IFN-{gamma} release specifically to either the entire (donor 1) or a part of the MM peptide panel (donors 2–5) (Fig. 9). The majority of these IFN-{gamma}-secreting, MM Ag-specific human T cells recognized A2.1+ MM targets, but not A2.1– NCI-H929 MM cells (Fig. 9). However, all MM-reactive human T cells were ignorant to peptide-pulsed T2 and MM targets in 51Cr-release killing assays (data not shown). These results suggest that the A2.1-restricted, PRDI-BF1- and XBP-1-specific human CD8+ T cell repertoire is affected by partial self tolerance.



View larger version (16K):
[in this window]
[in a new window]
  		FIGURE 9. Human PRDI-BF1- and XBP-1-specific T cell responses. Human T cells from 10 different A2.1+ healthy donors were stimulated with CD154-CD40-activated autologous B cells that had been loaded with either of the PRDI-BF1 377 and 401 peptides or the XBP-1 19 Ag. The IFN-{gamma} release of the 5 of 10 donor T cells that responded specifically to either the entire (donor 1) or a part of the MM peptide panel (donors 2–5) is shown. Results represent responses to T2 stimulators at the lowest Ag concentration tested (10–9 M) and to A2.1+ L363 and U266 MM targets. HIV-RT peptide-pulsed T2 and the A2.1– MM target NCI-H929 served as negative controls. The number of IFN-{gamma} spots is calculated per 1 x 105 responder T cells.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
Our studies demonstrate that key transcription factors which govern the terminal differentiation of B cells into plasma cells, such as PRDI-BF1 and XBP-1, provide naturally processed peptide epitopes for A2.1-restricted, MM- and tumor-reactive CTL. We cannot preclude that the differential pattern of target cell lysis obtained with PRDI-BF1 (377–386)-, (401–410)- and (402–410)-reactive CTL is due to their differential sensitivity to cysteine modification of natural PRDI-BF-1-derived peptide epitopes. It is likely that the specific CTL-based targeting of PRDI-BF1 and XBP-1 transcriptional regulators, which are essential for terminal B cell differentiation into all plasma cell types (16, 20), would not only allow to encompass almost all types of MM, but may also prevent the risk of malignant plasma cell escape from immune recognition by the selection of PRDI-BF1- or XBP-1-loss variants. This consideration is also emphasized by recent data demonstrating that the remarkable therapeutic efficacy of proteasome inhibitors in the treatment of MM (46) is coattributable to their effect on XBP-1 (47). By disrupting the unfolded protein response, a signaling pathway evoked by stress that is required for the correct folding and transport of proteins from secretory cells, such as plasma cells, they eventually lead to a functional deficiency of XBP-1 resulting in increased apoptosis of MM cells (47).

As expected by the broader expression pattern of PRDI-BF1 and XBP-1 (16, 17, 20, 25, 26, 38, 41), our studies revealed that CTL recognition was not limited to MM cells. We found that malignant melanoma targets were efficiently lysed by PRDI-BF1- and XBP-1-reactive CTL, and recognition by XBP-1-specific CTL was extended to breast cancer and hepatocellular carcinoma cells. However, normal BM cells were not recognized by the due CTL and low-to-intermediate level cytotoxicity to mature DC and purified B cells was only observed with a subset of PRDI-BF1- and XBP-1-reactive effector cells, but not with PRDI-BF1 (377–386)- or XBP-1 (18–27)-reactive CTL. Consistent with these findings, more recent results indicate that in lymphoid organs, high-level expression of Blimp-1 is restricted to Ab-secreting cells with a minority of cells expressing low level and the vast majority of cells expressing no Blimp-1 at all (48). Yet, the broader pattern of PRDI-BF1- and XBP-1-specific target cell recognition could nevertheless be accompanied by the risk of autoimmune T cell responses. Careful evaluation of the effect of Blimp-1- and mouse XBP-1-specific T cells in suitable preclinical mouse models is necessary to address this concern.

Our results suggest that the A2.1-restricted, PRDI-BF1- and XBP-1-specific human CD8+ T cell repertoire, in contrast to A2.1 Tg mice, is affected by partial self tolerance. It was by far more difficult to obtain a human T cell response to these peptides, consistent with an effect on the repertoire due to partial self tolerance. Provided that autoimmunity is controlled, limited to defined tissues, or absent (as indicated for PRDI-BF1 (377–386)), the findings reported here offer the appealing therapeutic possibility of turning human T lymphocytes into efficient MM- and tumor-reactive CTL by gene transfer of PRDI-BF1- and XBP-1-specific TCR (49), as has been recently demonstrated in our laboratory with A2.1-restricted, MDM2 (81–88)- and p53 (264–272)-specific TCR obtained by circumventing self tolerance in Tg mice (14, 50). Allo-MHC-restricted TCR (51), in vitro mutated and selected TCR of high affinity (52, 53), and TCR-like molecules (54) are due therapeutic instruments of human origin (55).

Finally, the presented experiments provide the basis to consider a new class of proteins, defined transcription factors, to tackle MM and other malignancies. Apart from PRDI-BF1 and XBP-1, another transcription factor, IFN regulatory factor 4 (IRF4), also known as MM oncogene 1 (MUM1), was shown to be inherently involved in plasmacytic differentiation (56). Recent studies reported on the recurrent genetic aberration in MM that juxtaposes the IgH locus to the IRF4 gene, resulting in the overexpression of IRF4 (57). Therefore, we propose that IRF4 is likely to serve as another candidate MM-associated Ag. Gene expression profiling in plasma cells revealed that these cells display a highly specialized genetic program including the expression of unique sets of known and novel transcription factors (24, 58) that may also provide novel target molecules for CTL-based immunotherapy of MM.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by grants from the Deutsche Forschungsgemeinschaft (SFB 432 A3; to M.T.), the Laupitz Foundation (to M.T.), and the Mainzer Forschungsfoerderungsprogramm des Fachbereichs Medizin (MAIFOR) program (to C.L. and M.T.). C.L. is the recipient of a Lady Tata Memorial Trust Career Development Award. M.T. is a José Carreras Leukemia Foundation Professor. Back

2 Address correspondence and reprint requests to Dr. Carina Lotz at the current address: Department of Immunology (IMM1), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037. E-mail address: clotz{at}scripps.edu Back

3 Abbreviations used in this paper: MM, multiple myeloma; MUC1, mucin 1; XBP-1, X box-binding protein 1; Blimp-1, B lymphocyte-induced maturation protein 1; PRDI-BF1, positive regulatory domain I-binding factor 1; Tg, transgenic; FluM1, influenza virus matrix protein; hTyr, human tyrosinase; VSV-N, vesicular stomatitis virus nucleoprotein; HIV-RT, HIV type 1 reverse transcriptase; B-LCL, B lymphoblastoid cell line; B-ALL, pre B acute leukemia cell line; DC, dendritic cell; BM, bone marrow; Ct, threshold cycle; IRF4, IFN regulatory factor 4. Back

Received for publication May 12, 2004. Accepted for publication May 2, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Blade, J., D. H. Vesole, M. Gertz. 2003. Controversy in hematology: transplantation for multiple myeloma: who, when, how often: high-dose therapy in multiple myeloma. Blood 102: 3469-3477.[Free Full Text]
  2. Gahrton, G., H. Svensson, M. Cavo, J. Apperly, A. Bacigalupo, B. Bjorkstrand, J. Blade, J. Cornelissen, A. de Laurenzi, T. Facon, et al 2001. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. 113: 209-216.[Medline]
  3. Tricot, G., D. H. Vesole, S. Jagannath, J. Hilton, N. Munshi, B. Barlogie. 1996. Graft-versus-myeloma effect: proof of principle. Blood 87: 1196-1198.[Abstract/Free Full Text]
  4. Le Blanc, R., S. Montminy-Metivier, R. Belanger, L. Busque, D. Fish, D. C. Roy, J. Kassis, J. Boileau, R. Lavallee, D. Belanger, et al 2001. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. 28: 841-842.[Medline]
  5. Orsini, E., R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, J. Ritz. 2003. Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 63: 2561-2568.[Abstract/Free Full Text]
  6. Salama, M., T. Nevill, D. Marcellus, P. Parker, M. Johnson, A. Kirk, D. Porter, S. Giralt, J. E. Levine, W. Drobyski, et al 2000. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 26: 1179-1184.[Medline]
  7. Lokhorst, H. M., A. Schattenberg, J. J. Cornelissen, M. H. van Oers, W. Fibbe, I. Russell, N. W. Donk, L. F. Verdonck. 2000. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J. Clin. Oncol. 18: 3031-3037.[Abstract/Free Full Text]
  8. Stevenson, F. K., K. C. Anderson. 2000. Preparing the ground for vaccination against multiple myeloma. Immunol. Today 21: 170-171.[Medline]
  9. Pellat-Deceunynck, C.. 2003. Tumour-associated antigens in multiple myeloma. Br. J. Haematol. 120: 3-9.[Medline]
  10. Van Baren, N., F. Brasseur, D. Godelaine, G. Hames, A. Ferrant, F. Lehmann, M. Andre, C. Ravoet, C. Doyen, G. C. Spagnoli, et al 1999. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 94: 1156-1164.[Abstract/Free Full Text]
  11. Brossart, P., A. Schneider, P. Dill, T. Schammann, F. Grunebach, S. Wirths, L. Kanz, H. J. Buhring, W. Brugger. 2001. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 61: 6846-6850.[Abstract/Free Full Text]
  12. Milazzo, C., V. L. Reichardt, M. R. Müller, F. Grünebach, P. Brossart. 2003. Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101: 977-982.[Abstract/Free Full Text]
  13. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993-11997.[Abstract/Free Full Text]
  14. Stanislawski, T., R. H. Voss, C. Lotz, E. Sadovnikova, R. A. Willemsen, J. Kuball, T. Ruppert, R. L. Bolhuis, C. J. Melief, C. Huber, et al 2001. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol. 2: 962-970.[Medline]
  15. Shapiro-Shelef, M., K. Calame. 2004. Plasma cell differentiation and multiple myeloma. Curr. Opin. Immunol. 16: 226-234.[Medline]
  16. Reimold, A. M., N. N. Iwakoshi, J. Manis, P. Vallabhajosyula, E. Szomolanyi-Tsuda, E. M. Gravallese, D. Friend, M. J. Grusby, F. Alt, L. H. Glimcher. 2001. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412: 300-307.[Medline]
  17. Turner, C. A., Jr, D. H. Mack, M. M. Davis. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell 77: 297-306.[Medline]
  18. Schliephake, D. E., A. Schimpl. 1996. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/anti-µ F(ab')2-co-stimulated B lymphocytes. Eur. J. Immunol. 26: 268-271.[Medline]
  19. Angelin-Duclos, C., G. Cattoretti, K. I. Lin, K. Calame. 2000. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165: 5462-5471.[Abstract/Free Full Text]
  20. Shapiro-Shelef, M., K. I. Lin, L. J. McHeyzer-Williams, J. Liao, M. G. McHeyzer-Williams, K. Calame. 2003. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells. Immunity 19: 607-620.[Medline]
  21. Ghosh, N., I. Gyory, G. Wright, J. Wood, K. L. Wright. 2001. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276: 15264-15268.[Abstract/Free Full Text]
  22. Borson, N. D., M. Q. Lacy, P. J. Wettstein. 2002. Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma. Blood 100: 4629-4639.[Abstract/Free Full Text]
  23. Nagy, M., B. Chapuis, T. Matthes. 2002. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br. J. Haematol. 116: 429-435.[Medline]
  24. Zhan, F., E. Tian, K. Bumm, R. Smith, B. Barlogie, J. Shaughnessy, Jr. 2003. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 101: 1128-1140.[Abstract/Free Full Text]
  25. Chang, D. H., C. Angelin-Duclos, K. Calame. 2000. BLIMP-1: trigger for differentiation of myeloid lineage. Nat. Immunol. 1: 169-176.[Medline]
  26. Liou, H. C., R. Eddy, T. Shows, B. Lisowska-Grospierre, C. Griscelli, C. Doyle, J. Mannhalter, M. Eibl, L. H. Glimcher. 1991. An HLA-DR {alpha} promoter DNA-binding protein is expressed ubiquitously and maps to human chromosomes 22 and 5. Immunogenetics 34: 286-292.[Medline]
  27. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185: 833-841.[Abstract/Free Full Text]
  28. Sherman, L. A., S. V. Hesse, M. J. Irwin, D. La Face, P. Peterson. 1992. Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8. Science 258: 815-818.[Abstract/Free Full Text]
  29. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert. 1994. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153: 5586-5592.[Abstract]
  30. Tsomides, T. J., B. D. Walker, H. N. Eisen. 1991. An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA 88: 11276-11280.[Abstract/Free Full Text]
  31. Lotz, C., E. A. Ferreira, I. Drexler, S. A. Mutallib, C. Huber, G. Sutter, M. Theobald. 2004. Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man. Int. J. Cancer 108: 571-579.[Medline]
  32. Kuckelkorn, U., E. A. Ferreira, I. Drung, U. Liewer, P. M. Kloetzel, M. Theobald. 2002. The effect of the interferon-{gamma}-inducible processing machinery on the generation of a naturally tumor-associated human cytotoxic T lymphocyte epitope within a wild-type and mutant p53 sequence context. Eur. J. Immunol. 32: 1368-1375.[Medline]
  33. Kuball, J., M. Schuler, F. E. Antunes, W. Herr, M. Neumann, L. Obenauer-Kutner, L. Westreich, C. Huber, T. Wölfel, M. Theobald. 2002. Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther. 9: 833-843.[Medline]
  34. Goidin, D., A. Mamessier, M. J. Staquet, D. Schmitt, O. Berthier-Vergnes. 2001. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and {beta}-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal. Biochem. 295: 17-21.[Medline]
  35. Parker, K. C., M. A. Bednarek, J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152: 163-175.[Abstract]
  36. Rammensee, H., J. Bachmann, N. P. Emmerich, O. A. Bachor, S. Stevanovic. 1999. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50: 213-219.[Medline]
  37. Chen, W., J. W. Yewdell, R. L. Levine, J. R. Bennink. 1999. Modification of cysteine residues in vitro and in vivo affects the immunogenicity and antigenicity of major histocompatibility complex class I-restricted viral determinants. J. Exp. Med. 189: 1757-1764.[Abstract/Free Full Text]
  38. Munshi, N. C., T. Hideshima, D. Carrasco, M. Shammas, D. Auclair, F. Davies, N. Mitsiades, C. Mitsiades, R. S. Kim, C. Li, et al 2004. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood 103: 1799-1806.[Abstract/Free Full Text]
  39. Meadows, L., W. Wang, J. M. den Haan, E. Blokland, C. Reinhardus, J. W. Drijfhout, J. Shabanowitz, R. Pierce, A. I. Agulnik, C. E. Bishop, et al 1997. The HLA-A*0201-restricted H-Y antigen contains a posttranslationally modified cysteine that significantly affects T cell recognition. Immunity 6: 273-281.[Medline]
  40. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771.[Medline]
  41. Kokura, K., T. Kishimoto, T. Tamura. 2000. Identity between rat htf and human xbp-1 genes: determination of gene structure, target sequence, and transcription promotion function for HTF. Gene 241: 297-307.[Medline]
  42. Keller, A. D., T. Maniatis. 1991. Identification and characterization of a novel repressor of {beta}-interferon gene expression. Genes Dev. 5: 868-879.[Abstract/Free Full Text]
  43. Kishimoto, T., K. Kokura, N. Ohkawa, Y. Makino, M. Yoshida, S. Hirohashi, S. Niwa, M. Muramatsu, T. Tamura. 1998. Enhanced expression of a new class of liver-enriched b-Zip transcription factors, hepatocarcinogenesis-related transcription factor, in hepatocellular carcinomas of rats and humans. Cell Growth Differ. 9: 337-344.[Abstract]
  44. Medema, J. P., D. H. Schuurhuis, D. Rea, J. van Tongeren, J. de Jong, S. A. Bres, S. Laban, R. E. Toes, M. Toebes, T. N. Schumacher, et al 2001. Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J. Exp. Med. 194: 657-667.[Abstract/Free Full Text]
  45. Shresta, S., T. A. Graubert, D. A. Thomas, S. Z. Raptis, T. J. Ley. 1999. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity 10: 595-605.[Medline]
  46. Richardson, P. G., B. Barlogie, J. Berenson, S. Singhal, S. Jagannath, D. Irwin, S. V. Rajkumar, G. Srkalovic, M. Alsina, R. Alexanian, et al 2003. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 348: 2609-2617.[Abstract/Free Full Text]
  47. Lee, A. H., N. N. Iwakoshi, K. C. Anderson, L. H. Glimcher. 2003. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 100: 9946-9951.[Abstract/Free Full Text]
  48. Kallies, A., J. Hasbold, D. M. Tarlinton, W. Dietrich, L. M. Corcoran, P. D. Hodgkin, S. L. Nutt. 2004. Plasma cell ontogenity defined by quantitative changes in Blimp-1 expression. J. Exp. Med. 200: 967-977.[Abstract/Free Full Text]
  49. Kessels, H. W., M. C. Wolkers, M. D. van den Boom, M. A. van der Valk, T. N. Schumacher. 2001. Immunotherapy through TCR gene transfer. Nat. Immunol. 2: 957-961.[Medline]
  50. Kuball, J., F. W. Schmitz, R.-H. Voss, E. Antunes Ferreira, R. Engel, P. Guillaume, S. Strand, P. Romero, C. Huber, et al 2005. Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 22: 117-129.[Medline]
  51. Stauss, H. J.. 1999. Immunotherapy with CTLs restricted by nonself MHC. Immunol. Today 20: 180-183.[Medline]
  52. Holler, P. D., P. O. Holman, E. V. Shusta, S. O’Herrin, K. D. Wittrup, D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97: 5387-5392.[Abstract/Free Full Text]
  53. Kessels, H. W., M. D. van den Boom, H. Spits, E. Hooijberg, T. N. Schumacher. 2000. Changing T cell specificity by retroviral T cell receptor display. Proc. Natl. Acad. Sci. USA 97: 14578-14583.[Abstract/Free Full Text]
  54. Chames, P., R. A. Willemsen, G. Rojas, D. Dieckmann, L. Rem, G. Schuler, R. L. Bolhuis, H. R. Hoogenboom. 2002. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. 169: 1110-1118.[Abstract/Free Full Text]
  55. Heemskerk, M. H., M. Hoogeboom, R. A. de Paus, M. G. Kester, M. A. van der Hoorn, E. Goulmy, R. Willemze, J. H. Falkenburg. 2003. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved {alpha} joining region. Blood 102: 3530-3540.[Abstract/Free Full Text]
  56. Mittrucker, H. W., T. Matsuyama, A. Grossman, T. M. Kundig, J. Potter, A. Shahinian, A. Wakeham, B. Patterson, P. S. Ohashi, T. W. Mak. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275: 540-543.[Abstract/Free Full Text]
  57. Iida, S., P. H. Rao, M. Butler, P. Corradini, M. Boccadoro, B. Klein, R. S. Chaganti, R. Dalla-Favera. 1997. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat. Genet. 17: 226-230.[Medline]
  58. Underhill, G. H., D. George, E. G. Bremer, G. S. Kansas. 2003. Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood 101: 4013-4021.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
S. Desai, S. C. E. Bolick, M. Maurin, and K. L. Wright
PU.1 Regulates Positive Regulatory Domain I-Binding Factor 1/Blimp-1 Transcription in Lymphoma Cells
J. Immunol., November 1, 2009; 183(9): 5778 - 5787.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
I. G. Schuster, D. H. Busch, E. Eppinger, E. Kremmer, S. Milosevic, C. Hennard, C. Kuttler, J. W. Ellwart, B. Frankenberger, E. Nossner, et al.
Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies
Blood, October 15, 2007; 110(8): 2931 - 2939.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lotz, C.
Right arrow Articles by Theobald, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lotz, C.
Right arrow Articles by Theobald, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS